Quel est le prix pour Ember Therapeutics, Inc. (EMBT)

Le prix pour Ember Therapeutics, Inc. (EMBT) est $0.0001

Quelle est la capitalisation boursière pour Ember Therapeutics, Inc. (EMBT)

La capitalisation boursière pour Ember Therapeutics, Inc. (EMBT) est $398.00

Ember Therapeutics, Inc. (EMBT) Ratio P/S

Ember Therapeutics, Inc. operates as a biopharmaceutical company currently in its clinical development phase. Its core mission involves exploring the therapeutic applications of bone morphogenetic protein-7 (BMP-7) to engineer regenerative treatments. These innovative therapies are designed to alter the course of osteoarthritis, reverse insulin resistance, and inhibit or undo organ fibrosis in diseases such as chronic kidney disease and Alport's syndrome, alongside metabolic conditions like obesity and type 2 diabetes. Among its leading BMP-7-based drug candidates, MT-006 has successfully completed a Phase 2a clinical trial focused on osteoarthritis. Furthermore, MT-007, aimed at CKD and Alport syndrome; MT-008, specifically for Alport syndrome; and MT-009, targeting metabolic disease, have all concluded their preclinical trial phases. The company also maintains a substantial intellectual property portfolio, encompassing approximately 450 patents related to BMP-7, its associated protein families, various derivatives, novel delivery systems, specialized formulations, supporting clinical data, and materials produced under current good manufacturing practices. Ember Therapeutics, Inc. was established in 2010 and is headquartered in New York, New York.

Année	Ratio P/S	Changez
Pas assez de données pour les dates fournies.

Année

Ratio P/S

Changez

Pas assez de données pour les dates fournies.

Entreprise	Ratio P/S	Différence de Ratio P/S	Pays
Vertex Pharmaceuticals Incorporated VRTX.US	9.88	-	US
Argenx SE ARGX.US	10.30	-	NL
Lonza Group AG LONN.SW	-	-	CH
UCB S.A. UCB.BR	4.98	-	BE
Samsung Biologics Co.,Ltd. 207940.KS	-	-	KR

Entreprise

Ratio P/S

Différence de Ratio P/S

Pays